Table 1.

Characteristics of SVT cases.

Patient	A	B	C		D	E	F
Case	1	2	3	4	5	6	7
Age	1 month	15 months	2 years	3 years	3 years	3 years	6 years
Sex	M	M	F	F	M	F	F
History of asthma	no	no	yes	yes	yes	yes	no
History of SVT	no	no	yes	yes	yes	no	no
History of heart disease	yes	no	no	no	no	no	no
Family history of arrhythmia	no	no	no	no	yes	no	no
Number of days of illness	1	3	1	1	2	1	2
Pre-hospital beta-2 agonist	N/A	1 dose albuterol	2 doses albuterol	levalbuterol every 4 hours for 1 day	2 doses albuterol	2 doses levalbuterol	4 doses albuterol
Beta-2 agonist before SVT	6 doses of albuterol 2.5 mg over 12 hours with decreasing interval (15 mg total)	5 doses of albuterol 2.5 mg over 48 hours (12.5 mg total)	2 doses of levalbuterol 0.63 mg over 1 hour (1.26 mg total)	Arrived to ED in SVT after 2.5 mg albuterol at PCP office	Arrived to ED in SVT after 1.26 mg levalbuterol at PCP office	albuterol 10 mg/hr for 4 hours	albuterol 20 mg/hr for 5 hours
Patient location at onset of SVT	ICU	Hospital Floor	ED	PCP	PCP	ICU	ICU
Conversion	adenosine 0.4mg (0.1 mg/kg)	spontaneous	2 doses adenosine 1.3 mg (0.1 mg/kg)	adenosine 1.4 mg (0.1 mg/kg) then 2 doses 2.8 mg (0.2 mg/kg)	3 doses adenosine 0.6 mg (0.1 mg/kg) then electrical cardioversion	adenosine 1.5 mg (0.1 mg/kg)	adenosine 12 mg (0.6 mg/kg)
Disposition Physician-stated cause for SVT	ICU albuterol	ICU mediastinal mass	ICU levalbuterol	floor albuterol	floor levalbuterol	ICU undiagnosed WPW	ICU albuterol